Results 41 to 50 of about 907 (150)

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

International Journal of Cancer, EarlyView.
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto, Sophie Gibert, Caroline Delmas, David Tougeron, Amaury Paumier, Alexandre Taillez, Samuel Le Sourd, Delphine Argo Leignel, Philippe Ronchin, Ariane Darut Jouve, Véronique Vendrely, Olivier Riou, Jérôme Martin‐Babau, Thomas Leroy, Laurent Quéro, Naïma Hanoun, Pierre Cordelier, Veronica Pezzella, Jean Pierre Delord, Rosine Guimbaud, Elizabeth Moyal, Catherine Seva   +21 more
wiley   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

Early detection of uterine corpus endometrial carcinoma utilizing plasma cfDNA fragmentomics

BMC Medicine
Background Uterine corpus endometrial carcinoma (UCEC) is a prevalent gynecologic malignancy with a favorable prognosis if detected early. However, there is a lack of accurate and reliable early detection tests for UCEC.
Jing Liu, Dan Hu, Yibin Lin, Xiaoxi Chen, Ruowei Yang, Li Li, Yanyan Zhan, Hua Bao, LeLe Zang, Mingxuan Zhu, Fei Zhu, Junrong Yan, Dongqin Zhu, Huiqi Zhang, Benhua Xu, Qin Xu   +15 more
doaj   +1 more source

The circulating cell-free DNA landscape in sepsis is dominated by impaired liver clearance

Cell Genomics
Summary: Circulating cell-free DNA (cfDNA) is a promising molecular biomarker, but its role in severe infection is unclear. Here, we profile cfDNA from sepsis patients and controls, demonstrating a 41-fold increase during disease.
Kiki Cano-Gamez, Patrick Maclean, Masato Inoue, Sakineh Hussainy, Elisabeth Foss, Chloe Wainwright, Hanyu Qin, Stuart McKechnie, Chun-Xiao Song, Julian C. Knight   +9 more
doaj   +1 more source

Saliva Liquid Biopsy for Detection of Oral and Systemic Diseases

Journal of Periodontal Research, EarlyView.
This Review summarizes and discusses the biological foundations and major classes of salivary biomarkers, outlines collection methods and analytical protocols for saliva‐based liquid biopsy, and technological convergences driven by multi‐omics approaches, artificial intelligence, and point‐of‐care devices in the application of oral and systemic ...
Irene Choi, Aaron Zander, Bradley Chan, Leila Syedmoradi, Dev Trivedi, Karolina Elżbieta Kaczor‐Urbanowicz, Fang Wei, Neeti Swarup, Trinity Chan, Mario Romandini, David T. W. Wong   +10 more
wiley   +1 more source

Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium

International Journal of Cancer, Volume 159, Issue 8, Page 1873-1883, 15 October 2026.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms ...
Christine Worthington, Maria Raitses‐Gurevich, Giulio Innamorati, Phil A. Hart, Thomas M. Wilkie, Noam Tau, Dana Brin, Doron Yablecovitch, Ido Laish, Dove Keith, Kurt Giles, Jennifer B. Permuth, Diane M. Simeone, George Zogopoulos, Randall E. Brand, John J. Graff, Julie Earl, On behalf of the PRECEDE Consortium, Nikhil Agarwal, Laufey Amundadottir, Michelle Anderson, Ajay Bansal, Todd Bauer, Georg Beyer, Yan Bi, Erkut Borazanci, Randy Brand, Teri Brentnall, Carol Burke, Darren Carpizo, Saurabh Chawla, Daniel Chung, Sourat Darabi, Michael Demeure, Timothy Donahue, Julie Earl, Whitney Espinel, James Farrell, Vigdís Fjóla Stefánsdóttir, Jared Forrester, Eitan Friedman, Paul Franklin, Srinivas Gaddam, Ana García García de Paredes, Steven Gallinger, Talia Golan, Ora Gordon, Robert Grant, William Greenhalf, Eli Marie Grindedal, Aaron Grossberg, Brenda Hafers, Heather Hannon, Sigurdís Haraldsdóttir, Stefán Haraldsson, Peter Hegyi, Melissa Hogg, Amy de Haar‐Holleman, Susan Hong, Greg Idos, Edward Kim, Fay Kastrinos, Bryson Katona, Vivek Kaul, Derk Klatte, Kelsey Klute, Kimberly Ku, Sonia Kupfer, Rich Kwon, Rosario Ligresti, James James Lin, Wei‐Chih (David) Liao, Aimee Lucas, Nipun Merchant, Andrew Metz, Whitney Maxwell, James McLoughlin, Sodech Miclette, Xavier Molero, Leticia Moreira, Takuji Okusaka Chigusa Morizane, Joanne Ngeow, Salvatore Paiella, Jennifer Permuth, Maricel Purcell, Joshua Raff, Vineet Rolston, Intan Schrader, Rosie Sears, Yan‐Shen Shan, Diane Simeone, Jens Siveke, Brett Sheppard, Tyler Stevens, Elena Stoffel, Dan Sussman, Margaret Tempero, Jose Trevino, Jennifer Valerin, Eva Vaquero, Ray Wadlow, Garrett Ward, David Weinberg, Ronald Wolf, Dana Zakalik, George Zogopoulos   +105 more
wiley   +1 more source

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

Cytopathology, Volume 37, Issue 5, Page 438-448, September 2026.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati, V. Callegari, A. Ancora, M. Palmieri, B. Riccò, E. Cabitza, L. Trudu, K. Di Emidio, C. Chiavelli, A. Eccher, I. Mastrolia, V. Catani, S. Bettelli, G. Guaitoli, M. Dominici, F. Bertolini   +15 more
wiley   +1 more source

DeepFRAG: a method for cancer detection based on DNA fragmentomics and deep learning. [PDF]

Bioinform Adv
Abstract Motivation Cancer screening using liquid biopsy technology has become standard in modern clinical and preventive oncology. This method analyzes cell-free DNA (cfDNA) circulating in a patient’s bloodstream.
Koch A, Giladi E.
europepmc   +4 more sources

Cell-Free Mitochondrial DNA in Cell Culture Supernatant: Fragment Size Analysis and FBS Contamination Assessment

DNA
Background/Objectives: Circulating cell-free DNA (cfDNA) consists of genomic DNA (cf-nDNA) and mitochondrial DNA (cf-mtDNA) fragments released from cells primarily through apoptosis and necrosis.
Patrizia Cesare, Sabrina Colafarina, Antonella Bonfigli, Anna Rita Volpe, Massimo Aloisi, Osvaldo Zarivi, Anna Maria Giuseppina Poma   +6 more
doaj   +1 more source

Blood‐Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations

International Journal of Cancer, Volume 159, Issue 4, Page 1028-1041, 15 August 2026.
Early detection of colorectal cancer via population‐based screening programs can reduce incidence and mortality, but current screening approaches are limited. This systematic review evaluated the screening potential of blood‐based circulating tumor DNA assays in asymptomatic screening populations.
Caroline Ledertoug Kahn, Maria Wissing Rasmussen, Jakob Kleif, Inge Søkilde Pedersen, Christina Therkildsen   +4 more
wiley   +1 more source